Browse VariZIG™ VariZIG™ Home Patients and Families Healthcare Professionals Plasma Safety VariZIG™ Product Monograph & Package Insert VariZIG™, licensed in Canada, is a highly purified and specialized antibody product, developed as a preventive measure against the varicella zoster virus, which causes a viral infection called "chickenpox". VariZIG™ prevents or reduces the severity of maternal varicella infections (chickenpox) in non-immune pregnant women who had been exposed to individuals infected with the varicella zoster virus.

Available in the U.S.
VariZIG™ (Varicella Zoster Immune Globulin (Human)) is available under an investigational new drug application (IND) expanded access protocol VariZIG™ may be requested for individuals who have been exposed to varicella, at increased risk of complications, and for whom informed consent is obtained.

An Expanded Access Protocol enables health professionals to administer the investigational VariZIG™ to patients who meet the protocol's enrollment criteria. Additional information regarding the Expanded Access Protocol is available at http://www.fda.gov/cber/infosheets/mphvzig020806.htm

VariZIG™ is distributed in the USA by FFF Enterprises. When a healthcare professional identifies that a patient qualifies for the Expanded Access Protocol, they should contact FFF Enterprises directly at their 24-hour number: 1-800-843-7477